The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Sep 06, 2026
Snapshot (as of Sep 06, 2026): Royalty Pharma plc (RPRX) pays a $0.93 annual dividend ($0.23 quarterly), yielding 1.45% at $63.96/share. Next ex-dividend date 2026-08-14. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 1.45%
Annual Dividend: $0.93 per share
Payout Ratio: 48.9%
Ex-Dividend Date: 2026-08-14
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 7
Royalty Pharma plc dividend investors are buying into a unique model: the company acquires royalties on biopharmaceutical therapies rather than developing drugs itself, with a portfolio spanning roughly 35 marketed therapies across oncology, rare disease, and neuroscience. RPRX currently yields 1.45%, paying $0.9250 per share annually on a quarterly schedule, with the next ex-dividend date set for August 14, 2026. The last quarterly payment was $0.2350 per share. A beta of 0.43 makes this one of the lower-volatility names in healthcare, which suits income investors who prioritize price steadiness over a high headline yield.
Royalty Pharma plc pays out 48.9% of earnings as dividends, a payout ratio classified as moderate (40-60%). That level leaves meaningful room between the dividend and earnings, and the company's royalty-based model, which draws income from approximately 35 marketed therapies already generating sales, supports that payout without relying on a single product's commercial success. Royalty Pharma plc dividend safety gets its clearest test from portfolio concentration risk: royalties tied to development-stage candidates (roughly 20 in the pipeline) carry binary outcomes, and a wave of clinical failures could pressure future royalty income.
Over the past four years, Royalty Pharma plc dividend history shows a CAGR of 6.7% per year from 2021 to 2025. Per-share payments grew from $0.6800 to $0.8800 over that window (2026 is a partial year and excluded from the growth calculation). The smallest annual increase in the window was 4.8% in 2025, down from a peak increase of 11.8% in 2022. Growth is slowing, and at the current pace, income investors should expect mid-single-digit raises rather than double-digit bumps going forward.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +5.0% | $0.76 (2022) | $0.88 (2025) |
| 5-Year | +24.0% | $0.30 (2020) | $0.88 (2025) |
RPRX stock fits dividend investors who want low price volatility and steady, if unspectacular, income growth from a differentiated business model. The yield sits at low (below 2%), which is the central trade-off here: 1.45% is not a high-income figure, though it does run above the stock's own 5-year average yield of 1.24%, meaning the current entry point offers slightly more income than the historical norm. Four consecutive years of increases and a moderate payout ratio give the dividend a degree of durability. What an investor gains is a royalty-backed income stream with below-average market sensitivity. What they accept is a yield that will not satisfy investors who need current income above 2%.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-14 | $0.2350 |
| 2026-05-15 | $0.2350 |
| 2026-02-20 | $0.2350 |
| 2025-11-14 | $0.2200 |
| 2025-08-15 | $0.2200 |
| 2025-05-16 | $0.2200 |
| 2025-02-21 | $0.2200 |
| 2024-11-15 | $0.2100 |
| 2024-08-16 | $0.2100 |
| 2024-05-16 | $0.2100 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.7050 |
| 2025 | $0.8800 |
| 2024 | $0.8400 |
| 2023 | $0.8000 |
| 2022 | $0.7600 |
Project income from RPRX with the RPRX dividend calculator or track your full portfolio with the dividend tracker.